Antibody responses to HCV vaccine antigens in infection and vaccination

项目1摘要 HCV感染了近3%的世界人口，并且是肝硬化的主要原因， 癌一种能够阻止病毒传播的疫苗将成为公众非常有价值的工具 卫生系统。然而，HCV是抗原可变的，有效的疫苗必须靶向 病毒上保守的免疫表位HCV疫苗的一个重要目标是开发 将引发广泛中和抗体（bNAb）的抗原。拟议项目旨在 发现bNAb在疫苗接种和自然感染过程中靶向的表位， bnAb的进化途径。从人类研究中学到的知识将被应用 研究小鼠、豚鼠和非人灵长类动物免疫后的抗体应答 候选HCV疫苗抗原。这项研究将有助于揭示每种方法的利弊 动物模型作为未来HCV候选疫苗有效性研究的临床前模型。这 该项目将为开发广泛有效的HCV提供知识和工具 疫苗

Project 1 Summary HCV infects nearly 3% of the world population and is a leading cause of liver cirrhosis and cancer. A vaccine that can stop virus transmission will be a highly valuable tool for the public health system. However, HCV is antigenically variable and an effective vaccine must target conserved immune epitopes on the virus. An important goal in HCV vaccine is to develop antigens that will elicit broadly neutralizing antibodies (bNAbs). The proposed project aims to discover the epitopes targeted by bNAbs during vaccination and natural infection, and the evolutionary pathways of bnAbs. The knowledge learned from the human studies will be applied to studying the antibody responses in mice, guinea pigs and non-human primates immunized with candidate HCV vaccine antigens. The research will help uncover the pros and cons of each animal model as a preclinical model for efficacy study of future HCV vaccine candidates. This project will contribute to the knowledge and tools for the development of a broadly effective HCV vaccine.